In an attempt to evaluate the role of VIP in affective disorder, measurements of lymphocyte VIP receptors, and plasma and CSF VIP levels were made in unmedicated and lithium-treated euthymic bipolars and controls. Lithium decreased plasma (P=0.01) and CSF (P=0.05) VIP levels and increased the affinity (decreased the KD) of the VIP lymphocyte receptor (P<0.01). This effect may be relevant to the psychotropic action of lithium in manic-depressive illness.
- Bipolar affective illness - Lithium - Vasoactive intestinal peptide (VIP)
ASJC Scopus subject areas
- Clinical Psychology
- Psychiatry and Mental health